These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 31482511

  • 1. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
    Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y.
    Adv Ther; 2019 Oct; 36(10):2697-2711. PubMed ID: 31482511
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
    Durán-Garcia S, Lee J, Yki-Järvinen H, Rosenstock J, Hehnke U, Thiemann S, Patel S, Woerle HJ.
    Diabet Med; 2016 Jul; 33(7):926-33. PubMed ID: 26605991
    [Abstract] [Full Text] [Related]

  • 9. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M.
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [Abstract] [Full Text] [Related]

  • 10. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
    Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.
    Lancet; 2013 Oct 26; 382(9902):1413-23. PubMed ID: 23948125
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 26; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Jul 26; 12(4):249-57. PubMed ID: 25941160
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes.
    Inzucchi SE, Nauck MA, Hehnke U, Woerle HJ, von Eynatten M, Henry RR.
    Diabetes Obes Metab; 2015 Sep 26; 17(9):868-77. PubMed ID: 25974030
    [Abstract] [Full Text] [Related]

  • 20. Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
    Sheu WH, Park SW, Gong Y, Pinnetti S, Bhattacharya S, Patel S, Seck T, Woerle HJ.
    Curr Med Res Opin; 2015 Mar 26; 31(3):503-12. PubMed ID: 25629790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.